Compare Payoneer Global Inc (PAYO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Payoneer Global Inc vs GeneDx Holdings Corp — how do they compare? Payoneer Global Inc trades at $7.11 (market cap $2.42B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Payoneer Global Inc and GeneDx Holdings Corp are close in size by market cap, and Payoneer Global Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| PAYO | WGS | |
|---|---|---|
Market Cap | $2.42B | $2.56B |
Sector | Technology | Technology |
52-Week High | $7.18 | $167.51 |
52-Week Low | $4.27 | $34.51 |
Enterprise Value | $2.16B | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Payoneer Global (PAYO) trades at $7.13, down 0.56% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported Q2 2026 earnings of $0.02 per share, missing estimates, but revenue grew 10% year-over-year excluding interest. A pending acquisition by Nuvei for $7.40 per share announced in June 2026 is a key catalyst, though legal investigations question the deal's fairness.
The outlook hinges on the acquisition closing, offering a slight premium to current price, but execution risks and earnings volatility pose concerns. Analysts maintain a 60% buy rating, seeing value in cross-border payment growth, yet margin pressures and integration challenges post-acquisition are key investor risks.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
